Survodutide
BI 456906 · GLP-1/GCGR dual agonist · Zealand/Boehringer NASH peptide
A once-weekly GLP-1/glucagon receptor dual agonist by Boehringer Ingelheim in Phase 2/3 trials for NASH/MASH, obesity, and metabolic disease.
Half-Life
~6-7 days (once-weekly dosing)
MW
~4.5 kDa (estimated, acylated long-acting analog)
Amino Acids
29 AA
Evidence
Clinical
Regulatory Status
Phase 2/3 clinical trials (FRONTIER program) for NASH/MASH and obesity. Not yet approved. Boehringer Ingelheim + Zealand Pharma collaboration. Ongoing regulatory discussions.
In Plain English
A once-weekly injection that targets two receptors simultaneously: GLP-1 (suppresses appetite, lowers blood sugar) and glucagon (boosts liver fat burning and metabolism). Particularly exciting for fatty liver disease (NASH) because the glucagon component specifically drives the liver to burn its stored fat — something GLP-1-only drugs do less effectively.
Overview
Survodutide (BI 456906) is a long-acting dual GLP-1R/GCGR agonist developed by Boehringer Ingelheim in collaboration with Zealand Pharma. Currently in Phase 2/3 clinical trials (FRONTIER program) for non-alcoholic steatohepatitis (NASH, now termed MASH), obesity, and type 2 diabetes. The glucagon receptor component is particularly significant for NASH/liver disease, as GCGR activation drives hepatic fat oxidation and reduces liver steatosis. Phase 2 FRONTIER 1 trial demonstrated significant improvements in liver histology and NASH resolution scores. Represents a meaningful advance specifically for the NASH treatment space where no approved therapies existed for many years.
Common Formats
- Injectable (subcutaneous, once weekly)
- Pre-filled pen (clinical trial)
Storage Notes
Clinical formulation: 2-8°C. Protect from freezing and light. Do not shake.
Looking for multi-compound protocols?
Browse educational protocol discussions that include Survodutide.
Related Compounds
Semaglutide
A GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, demonstrating unprecedented weight loss results in clinical trials.
Tirzepatide
A dual GIP/GLP-1 receptor agonist with FDA approval showing up to 22% weight loss — superior to semaglutide in head-to-head trials.
Retatrutide
A triple GIP/GLP-1/glucagon receptor agonist in Phase III trials, showing over 24% weight loss — potentially the most powerful metabolic peptide in development.
Mazdutide
A once-weekly GLP-1/glucagon receptor dual agonist developed by Innovent Biologics, in Phase 3 trials for obesity and type 2 diabetes with up to 18% body weight loss.
Liraglutide
A once-daily GLP-1 receptor agonist with FDA approval for T2D and obesity, the predecessor to semaglutide with strong clinical evidence.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.